📗 Cite This Artifact
Combination Therapy and Multi-Target Strategies for CBS/PSP
Combination Therapy and Multi-Target Strategies for CBS/PSP
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Combination Therapy and Multi-Target Strategies for CBS/PSP</th>
</tr>
<tr>
<td class="label">Components</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">E2814 (anti-MTBR tau) + GLP-1 agonist</td>
<td>Tau reduction + neuroprotection</td>
</tr>
<tr>
<td class="label">Bepranemab + Minocycline</td>
<td>Tau neutralization + microglial modulation</td>
</tr>
<tr>
<td class="label">Components</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">CoQ10 + NACET</td>
<td>Complex I support + glutathione precursor</td>
</tr>
<tr>
<td class="label">MitoQ + Alpha-lipoic acid</td>
<td>Mitochondrial + cellular antioxidant</td>
</tr>
<tr>
<td class="label">Urolithin A + PQQ</td>
<td>Mitophagy + mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Components</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">GDNF + CSF1R inhibitor</td>
<td>Neuronal support + microglial depletion</td>
</tr>
<tr>
<td class="label">BDNF + TREM2 agonist</td>
<td>Synaptic support + microglial modulation</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">E2814 or BMS-986446</td>
<td>Trial protocol</td>
</tr>
<tr>
<td class="label">Lixisenatide</td>
<td>20 μg daily</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>300 mg BID</td>
</tr>
<tr>
Combination Therapy and Multi-Target Strategies for CBS/PSP
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Combination Therapy and Multi-Target Strategies for CBS/PSP</th>
</tr>
<tr>
<td class="label">Components</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">E2814 (anti-MTBR tau) + GLP-1 agonist</td>
<td>Tau reduction + neuroprotection</td>
</tr>
<tr>
<td class="label">Bepranemab + Minocycline</td>
<td>Tau neutralization + microglial modulation</td>
</tr>
<tr>
<td class="label">Components</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">CoQ10 + NACET</td>
<td>Complex I support + glutathione precursor</td>
</tr>
<tr>
<td class="label">MitoQ + Alpha-lipoic acid</td>
<td>Mitochondrial + cellular antioxidant</td>
</tr>
<tr>
<td class="label">Urolithin A + PQQ</td>
<td>Mitophagy + mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Components</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">GDNF + CSF1R inhibitor</td>
<td>Neuronal support + microglial depletion</td>
</tr>
<tr>
<td class="label">BDNF + TREM2 agonist</td>
<td>Synaptic support + microglial modulation</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">E2814 or BMS-986446</td>
<td>Trial protocol</td>
</tr>
<tr>
<td class="label">Lixisenatide</td>
<td>20 μg daily</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>300 mg BID</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>100 mg daily</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>Per neurology</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>1 mg daily</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>150 min/week</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>10 mg daily</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">1. Stabilization</td>
<td>Months 1-3</td>
</tr>
<tr>
<td class="label">2. Enhancement</td>
<td>Months 4-6</td>
</tr>
<tr>
<td class="label">3. Intensive</td>
<td>Months 7-12</td>
</tr>
<tr>
<td class="label">4. Maintenance</td>
<td>Ongoing</td>
</tr>
<tr>
<td class="label">Pair</td>
<td>Synergy Mechanism</td>
</tr>
<tr>
<td class="label">GLP-1 + Exercise</td>
<td>BDNF + insulin sensitivity</td>
</tr>
<tr>
<td class="label">NRF2 activator + Antioxidant</td>
<td>Transcription + direct scavenger</td>
</tr>
<tr>
<td class="label">Anti-tau + CSF1R</td>
<td>Reduce pathology + modulate microglia</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Rasagiline + Lithium</td>
<td>Serotonin syndrome risk</td>
</tr>
<tr>
<td class="label">Rasagiline + GLP-1</td>
<td>Limited data</td>
</tr>
<tr>
<td class="label">CoQ10 + Warfarin</td>
<td>May reduce INR</td>
</tr>
<tr>
<td class="label">Donepezil + Levodopa</td>
<td>May worsen dyskinesia</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Scientific Rationale</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Clinical Readiness</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>26/50</td>
</tr>
</table>
Combination therapy targeting multiple pathological pathways may provide superior outcomes compared to single-target approaches in CBS/PSP.
Rationale for Combination Therapy
CBS/PSP involves multiple convergent pathological mechanisms:
- Tau pathology: Aggregation, spreading, post-translational modifications
- Neuroinflammation: Microglial activation, cytokine elevation, complement
- Oxidative stress: Mitochondrial dysfunction, ROS accumulation
- Protein clearance: Autophagy-lysosome impairment, glymphatic dysfunction
Single-target approaches have shown limited efficacy; multi-target strategies address this challenge.
Evidence-Based Combinations
Anti-Tau + Anti-Inflammatory
Mitochondrial + Anti-Oxidant
Growth Factor + Immunomodulation
Multi-Target Strategies
Strategy 1: Disease Modification Stack
Rationale: Simultaneous targeting of tau, neuroinflammation, and oxidative stress
Strategy 2: Symptomatic + Disease Modification
Rationale: Optimize symptomatic control while adding disease-modifying components
Strategy 3: Sequential Therapy Protocol
Synergistic Mechanisms
Additive vs Synergistic
- Additive: Combined effect equals sum of individual effects
- Synergistic: Combined effect exceeds sum — target different pathways that amplify each other
Key Synergistic Pairs
Safety Considerations
Drug Interaction Matrix
Combination Risks
- Cumulative toxicity: Multiple agents may increase adverse effects
- Interaction complexity: Unknown interactions with novel combinations
- Regulatory status: Off-label combinations may not be covered
CBS/PSP Patient-Specific Protocol
For the 50-year-old male patient (alpha-synuclein negative, on levodopa/rasagiline):
NET Assessment
Patient Action Items
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
- [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
- [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
- [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
- [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-combination-therapy-multi-target-cbs-psp |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-f7acd07561a5 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-combination-therapy-multi-target-cbs-psp'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-combination-therapy-multi-target-cbs-psp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Combination Therapy and Multi-Target Strategies for CBS/PSP](http://scidex.ai/artifact/wiki-therapeutics-combination-therapy-multi-target-cbs-psp)
http://scidex.ai/artifact/wiki-therapeutics-combination-therapy-multi-target-cbs-psp